Precipio (NASDAQ:PRPO) Stock Rating Upgraded by Wall Street Zen

Precipio (NASDAQ:PRPO) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Precipio currently has an average rating of “Sell”.

Precipio Stock Performance

Shares of PRPO stock opened at $26.86 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.27 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average price of $24.21 and a 200-day moving average price of $21.94. Precipio has a 52 week low of $3.90 and a 52 week high of $29.53. The firm has a market capitalization of $47.06 million, a PE ratio of -32.76 and a beta of 1.22.

Institutional Investors Weigh In On Precipio

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in shares of Precipio by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 789 shares during the period. Renaissance Technologies LLC grew its position in Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 1,400 shares during the period. Susquehanna International Group LLP bought a new stake in Precipio during the third quarter valued at approximately $194,000. Evernest Financial Advisors LLC purchased a new stake in Precipio during the third quarter valued at approximately $374,000. Finally, Topline Capital Management LLC purchased a new stake in Precipio during the third quarter valued at approximately $1,158,000. Hedge funds and other institutional investors own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.